Neuren Pharmaceuticals Limited (AU:NEU) has released an update.
Neuren Pharmaceuticals is set to begin Phase 3 trials for NNZ-2591, a potential first-ever treatment for Phelan-McDermid syndrome (PMS), following a constructive FDA meeting. The trial will be a 13-week, randomized, double-blind study on children aged 3 to 12, with continuity in an open-label extension study until commercial launch. The company is finalizing efficacy endpoints with the FDA and proceeding with trial preparations, including site selection and drug manufacturing.
For further insights into AU:NEU stock, check out TipRanks’ Stock Analysis page.
